TCF3-HLF-Positive Acute Lymphoblastic Leukemia Reembling Burkitt Leukemia: Cell Morphologic and Immunophenotypic Findings

Meng-Ju Li, MD, MSc1,2; Chih-Hsiang Yu, PhD3,4; Shu-Wei Chou, MD4; Ying-Hui Su, MSc4,5; Kuang-Wen Liao, PhD2,6; Hsiu-Hao Chang, MD, PhD4; and Yung-Li Yang, MD, PhD4,7

JCO Precis Oncol 6:e2200236. © 2022 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License

Introduction

Acute lymphoblastic leukemia (ALL), the most common malignancy in childhood and adolescence, is a heterogeneous disease with various subtypes on the basis of distinct cell morphology and genetic alterations. These distinctions are noted through cytogenetic or molecular analyses and represent prognostic outcomes.1 By contrast, Burkitt leukemia (BL), a mature B lymphocyte neoplasm, is a highly aggressive hematologic malignancy characterized by uniformly medium-sized cells containing abundant basophilic cytoplasm, lipid vacuoles, and round nuclei with multiple nucleoli and clumped chromatin.1 It is associated with the proto-oncogene MYC at chromosomal locus 8q24.2

According to chromosomal analyses, approximately 80% of BL cases harbor a t(8;14) (q24;q32) translocation, which is typically used to diagnose the disease.1 Nonetheless, t(2;8) (p12;q24) and t(8;22) (q24;q11) may also occur.2 It is uncertain if true BL may be diagnosed without MYC translocations and hematologic cancers with BL morphology that lacked the typical BL immune phenotype or MYC rearrangement have been reported as BL-like ALL.3 Therefore, patients with leukemia with BL morphology and no MYC rearrangement may be diagnosed as BL-like ALL, BL without MYC rearrangement, or BL with cryptic MYC rearrangement, on the basis of next-generation sequencing.4 However, distinctions should be made because of differences in management and prognosis.

Because of front-line therapies derived from non-Hodgkin lymphoma Berlin-Frankfurt-Münster 95 (NHL-BFM95) protocol, pediatric BL is associated with promising outcomes. By contrast, some types of ALL with specific genetic alterations, such as t(17;19) TCF3-HLF fusion ALL, may harbor a dismal prognosis.5,6 In this study, we reported a pediatric case of TCF3-HLF fusion ALL wherein BL was initially diagnosed according to morphologic or immunophenotypic characteristics. The case emphasizes the importance of detecting cryptic fusion genes, especially those associated with considerable prognostic effects.

Case Report

A 7-year-old boy presented with diffuse petechiae and ecchymosis. Peripheral blood exhibited WBC, 26.94 x 10⁹/L; Hb, 96 g/L; platelet, 65 x 10⁹/L; circulating blast cells, 58%; and lactate dehydrogenase, 6,000 U/L. Bone marrow aspiration identified intermediate-sized blasts with immature lacy chromatin, marked nucleoli, and basophilic cytoplasm with abundant lipid vacuoles and granules (Fig 1A). Flow cytometry of bone marrow blasts was positive for CD19, CD10, CD20, CD33, CD79a, Cu, slgM, and lambda light chain (Fig 1B). Cytogenetic analysis revealed 46, XY, der(8), t(8:8), 19p+ [12]/46, XY, der(8), t(8:8), 19p+ [12], +6, +7, 19p+, −20, +22, +mar (1)/46, XY [12]. However, t(8;14) was negative. After receiving informed consent, common fusion transcripts, including ETV6-RUNX1, TCF3-PBX9, KMT2A rearrangement, and BCR-ABL1, were screened for but not detected. The patient’s bone marrow morphology and immunophenotype had overlapping features with BL. The initial CSF study showed CNS involvement.

The patient was initially treated with the Taiwan Pediatric Oncology Group (TPOG) 10 B-NHL protocol R4 arm (AA→BB→CC→AA→BB→CC) with concurrent rituximab administration. Detailed medications are listed in Appendix Table A1. The bone marrow study showed complete remission after course AA. The initial CSF study similarly showed the absence of blasts after four courses of triple intrathecal chemotherapy (methotrexate, hydrocortisone, and cytarabine). The patient underwent sequential treatment: course BB with rituximab, course CC with rituximab, and twice triple intrathecal chemotherapy.

The patient completed the first round of AA, BB, and CC treatment approximately 4 months after the initial diagnosis, during which time the bone marrow study showed 40% blasts. The morphology of blasts was similar to those identified at the initial diagnosis (Fig 2A). CNS relapse was also confirmed. Flow cytometry of...
bone marrow blasts was positive for CD19, CD10, CD33, CD79a, and Cu, but negative for CD20, sIgM, and lambda light chain (Fig 2B). Multiplex ligation-dependent probe amplification (MLPA) detected 19p deletion, indicating TCF3 translocations (Fig 3), and TCF3-HLF fusion was verified using reverse-transcription polymerase chain reaction (Fig 4). Thus, the diagnosis was changed from BL to TCF3-HLF fusion ALL.

FIG 1. TCF3-HLF-positive ALL resembles Burkitt leukemia. (A) Bone marrow aspirate smear shows intermediate-sized blasts with moderately condensed chromatin, inconspicuous nucleoli, and basophilic cytoplasm with cytoplasmic vacuoles (Liu’s staining; original magnification ×1,000, expanded view of the original image). (B) Immunophenotype showed positivity for CD19, CD10, CD20, CD33, CD79a, Cu, sIgM, and lambda light chain. ALL, acute lymphoblastic leukemia.

FIG 2. Distinct immunophenotype presentation at relapse. (A) Bone marrow aspirate smear at relapse demonstrates morphological features of BL (Liu’s staining; original magnification ×1,000, expanded view of the original image). (B) Immunophenotype was positive for CD19, CD10, CD33, CD79a, and Cu, but negative for CD20, sIgM, and lambda light chain. BL, Burkitt leukemia.
Seven months after the initial diagnosis, the patient had 7% residual leukemic cells detected by flow cytometry. He received haploidentical hematopoietic stem-cell transplantation sourced from the bone marrow. The conditioning regimen was total body irradiation and cyclophosphamide. Cell dosage was $9.55 \times 10^6 \text{CD34}^+ \text{cells/kg}$. The post-transplant course

**FIG 3.** MLPA identified 19p loss. Genomic DNA was analyzed using the SALSA MLPA kit (MRC-Holland, Amsterdam, the Netherlands) according to the manufacturer’s instructions, as previously described. The PCR fragments were separated by capillary electrophoresis on a Life Technologies 3500 Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA). MLPA data were analyzed using Coffalyser.Net v.140721.1958 (MRC-Holland, Amsterdam, the Netherlands). A probe ratio between 0.75 and 1.3 was considered within the normal range. A probe ratio below 0.75 or above 1.3 indicated deletion or gain, respectively. A probe ratio below 0.25 or above 1.8 indicated biallelic deletion or amplification, respectively. CN, copy number; MLPA, multiplex ligation-dependent probe amplification; PCR, polymerase chain reaction.

**FIG 4.** The TCF3-HLF fusion was verified by RT-PCR. Total RNA was isolated from bone marrow or blood samples using NucleoZol (MACHEREY-NAGEL, Düren, Germany). Complementary DNA (cDNA) was synthesized using Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA). A total of 1 µg total RNA was used for cDNA synthesis, which was performed according to the manufacturer’s instructions. The prepared reaction mix was incubated at 25°C for 10 minutes, followed by 60°C for 30 minutes; the reaction was then terminated by heating at 85°C for 5 minutes. PCR was performed using MyTaq HS Mix (Bioline, London, United Kingdom), and thermocycling was performed at 95°C for 60 seconds, followed by 38 cycles at 95°C for 15 seconds, 60°C for 15 seconds, and 72°C for 30 seconds. Final extension was done at 72°C for 5 minutes. Primers used for RT-PCR are sense (5’- GCCTGGCAGGAACGTCACAG -3’) and antisense (5’- TCAAGTCAGCCACCTCCTGGC -3’) primers. PCR products were visualized via agarose gel electrophoresis. Suspected bands were purified using the FavorPrep GEL/PCR Puriﬁcation Kit (FAVORGEN, Ping-Tung, Taiwan). Sanger sequencing was performed using an ABI 3730XL DNA analyzer (Thermo Fisher Scientific). The sequencing results were analyzed with SnapGene 4.1.3 software (GSL Biotech LLC, San Diego, CA). HLF, hepatic leukemia factor; RT-PCR, reverse-transcription polymerase chain reaction; TCF, transcription factor.
was uncomplicated with controllable grade II acute graft-versus-host disease. Nevertheless, a bone marrow study at 56 days post-transplantation showed 35% leukemic cells by flow cytometry, and the patient died after 2 months because of refractory disease and profound septic shock.

**Discussion**

This study reports a rare case of ALL in which the blast cells expressed typical morphologic features of BL (ie, mature B lymphoid antigens) but harbored TCF3-HLF fusion genes. The discrepant results obtained from different diagnostic tests (eg, morphologic interpretations, immunophenotyping, and karyotype) emphasized the significance of molecular genetic analysis and its crucial role in subgroup classification and prognostication.

TCF3, located at 19p, is rearranged with several genes in childhood ALL. A t(1;19) (q23;p13) translocation and TCF3-PBX1 fusion account for 5% of childhood ALL. Among reported BL-like ALL cases, only t(1;19) is repeatedly found in gene analyses, indicating that it plays a critical role in ALL resembling BL.

Recent next-generation sequencing studies on the pathogenesis of BL have revealed that mutations in the transcription factor TCF3 or its negative regulator ID3 occurred in approximately 70% of sporadic and immunodeficiency-related BL cases and 40% of endemic BL cases. TCF3 promotes survival and proliferation in lymphoid cells by activating the B-cell receptor/phosphatidylinositol 3-kinase signaling pathways and modulating the expression of cyclin D3, which is also mutated in 30% of BL.

The Berlin-Frankfurt-Munich protocol for pediatric Burkitt lymphoma/leukemia is promising. Few patients (7.9%; 157/1,979) demonstrate disease progression or relapse. Consistent with the World Health Organization consensus, which classified BL as a leukemic variant of Burkitt lymphoma, the TPOG treats patients with BL using the TPOG 10 B-NHL-R4 protocol. By contrast, patients with other forms of B-cell ALL are treated using the ALL protocol. However, TCF3-HLF-positive ALL is highly resistant to conventional chemotherapy and has a high rate of treatment failure despite treatment intensification and hematopoietic stem cell transplantation.

Molecular tests are becoming increasingly valuable in disease diagnosis, and genetic markers are widely used for subtype classification and prognostication. Detection of TCF3 rearrangement is crucial in diagnosing ALL, and distinguishing different TCF3 fusion genes is essential in risk stratification. However, conventional cytogenetic analysis may fail to detect t(8;14) or t(17;19) and underestimate cryptic fusion genes. The MLPA telomere kit circumvents this pitfall because of its higher sensitivity in detecting aneuploidy. Furthermore, it has a shorter turnaround time and higher sensitivity than conventional cytogenetics analysis, irrespective of the mitotic index.

This case report highlights the relevance of discrepant diagnostics, the importance of genetic marker identification, and the need for molecular test development and application. MLPA aids in the identification of copy-number variations and aneuploidy, which may be missed in conventional cytogenetic analysis. Thus, it may be a reasonable supplement to routine diagnostics in patients with childhood B-ALL, especially those with unknown subtypes of B-cell ALL and without metaphases or normal karyotype.

**AFFILIATIONS**

1Department of Pediatrics, National Taiwan University Hsin-Chu Hospital, Hsinchu, Taiwan
2Department of Biological Science and Technology, College of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan
3Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan
4Department of Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
5Childhood Cancer Foundation of the Republic of China, Taipei, Taiwan
6Institute of Molecular Medicine and Bioengineering, National Yang Ming Chiao Tung University, Hsinchu, Taiwan
7Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

**CORRESPONDING AUTHOR**

Yung-Li Yang, MD, PhD, College of Medicine, National Taiwan University, Department of Laboratory Medicine and Pediatrics, National Taiwan University Hospital, No. 7, Chung-Shan S. Rd, Taipei 100, Taiwan; e-mail: yangyl92@ntu.edu.tw.

**SUPPORT**

The study received funding support in the form of research grants from the Ministry of Science and Technology, Taiwan (MOST 108-2314-B-002-068 to M.J.L.), and the National Taiwan University Hospital Hsin-Chu Branch (107-HCH006, 109-HCH088, and 110-HCH015 to M.J.L.).

**DATA SHARING STATEMENT**

The data from the study will be made available by the authors on request.

**AUTHOR CONTRIBUTIONS**

Conception and design: Yung-Li Yang
Financial support: Meng-Ju Li, Yung-Li Yang
Administrative support: Kuang-Wen Liao, Yung-Li Yang
Provision of study materials or patients: Hsiu-Hao Chang, Yung-Li Yang
Collection and assembly of data: Meng-Ju Li, Shu-Wei Chou, Ying-Hui Su, Hsiu-Hao Chang, Yung-Li Yang
Data analysis and interpretation: Meng-Ju Li, Chih-Hsiang Yu, Ying-Hui Su, Kuang-Wen Liao, Yung-Li Yang
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.

No potential conflicts of interest were reported.

ACKNOWLEDGMENT

The authors express gratitude to the patient and his parents, who provided consent to publish this case.

REFERENCES

1. Swerdlow SH, Campo E, Pileri SA, et al: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375-2390, 2016
2. Hecht JL, Aster JC: Molecular biology of Burkitt’s lymphoma. J Clin Oncol 18:3707-3721, 2000
3. Sun J, Yu W, Zhang X: MEF2D-rearranged acute lymphoblastic leukemia resembles Burkitt lymphoma/leukemia. Ann Hematol 99:185-188, 2020
4. Woroniecka R, Rymkiewicz G, Szafron LM, et al: Cryptic MYC insertions in Burkitt lymphoma: New data and a review of the literature. PLoS One 17:e0263980, 2022
5. Woessmann W, Seidemann K, Mann G, et al: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95. Blood 105:948-958, 2005
6. Mouttet B, Vinti L, Ancliff P, et al: Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica 104:e244-e247, 2019
7. Yang CP, Hung JH, Jaing TH, et al: Treatment results of the TPOG-NHL92 protocols for childhood non-Hodgkin’s lymphomas in Taiwan: A report from the Taiwan Pediatric Oncology Group (TPOG). Acta Paediatr Taiwan 41:193-204, 2000
8. Vazquez-Reyes A, Bobadilla-Morales L, Barba-Barba C, et al: Aneuploidy identification in pre-B acute lymphoblastic leukemia patients at diagnosis by Multiplex Ligation-dependent Probe Amplification (MLPA). Leuk Res 59:117-123, 2017
9. Teachey DT, Hunger SP: Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol 162:606-620, 2013
10. Inaba H, Pui CH: Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J Clin Med 10:1926, 2021
11. Love C, Sun Z, Jim A, et al: The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44:1321-1325, 2012
12. Richter J, Schlesner M, Hoffmann S, et al: Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44:1316-1320, 2012
13. Woessmann W, Zimmermann M, Meinhardt A, et al: Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood 135:1124-1132, 2020
14. Li MJ, Liu HC, Yen HJ, et al: Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation. Pediatr Blood Cancer 64:234-241, 2017
15. Salim M, Heldt F, Thomay K, et al: Cryptic TCF3 fusions in childhood leukemia: Detection by RNA sequencing. Genes Chromosomes Cancer 61:22-26, 2022
16. Yu CH, Lin TK, Jou ST, et al: MLPA and DNA index improve the molecular diagnosis of childhood B-cell acute lymphoblastic leukemia. Sci Rep 10:11501, 2020

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
# APPENDIX

## TABLE A1. TPOG 10 B-NHL Protocol R4 Arm

| Drug                        | Dose                      | Days of Administration |
|-----------------------------|---------------------------|------------------------|
| **Cytoreductive prephase V**|                           |                        |
| Dexamethasone (orally/IV)   | 5 mg/m²                   | 1, 2                   |
| Dexamethasone (orally/IV)   | 10 mg/m²                  | 3-5                    |
| Cyclophosphamide (IV)       | 200 mg/m²                 | 1, 2                   |
| **Course AA**               |                           |                        |
| Dexamethasone (orally)      | 10 mg/m²                  | 1-5                    |
| Vincristine IV              | 1.5 mg m² (max 2 mg)      | 1                      |
| Ifosfamide (IV 1 hour)      | 800 mg/m²                 | 1-5                    |
| MTX (24-hour infusion)      | 5 g/m²                    | 1                      |
| TIT° (MTX, HC, AraC)        | 12, 12, 24 mg             | 1                      |
| Cytarabine (IV 1 hour)      | 150 mg/m² q12h            | 4, 5                   |
| Etoposide (IV 1 hour)       | 100 mg/m²                 | 4, 5                   |
| **Course BB**               |                           |                        |
| Dexamethasone (orally)      | 10 mg/m²                  | 1-5                    |
| Cyclophosphamide (1 hour ivf)| 200 mg/m²               | 1-5                    |
| Vincristine IV              | 1.5 mg m² (max 2 mg)      | 1                      |
| MTX (24-hour infusion)      | 5 g/m²                    | 1                      |
| TIT° (MTX, HC, AraC)        | 12, 12, 24 mg             | 1                      |
| Epirubicin (IV 1 hour)      | 25 mg/m²                  | 4, 5                   |
| **Course CC**               |                           |                        |
| Dexamethasone (orally)      | 20 mg/m²                  | 1-5                    |
| Vincristine (IV)            | 1.5 mg/m² (max 2 mg)      | 1                      |
| Cytarabine (IV 3 hour)      | 3 g/m² q12h               | 1, 2                   |
| Etoposide (IV 2 hour)       | 100 mg/m² q12h            | 3-5                    |
| TIT° (MTX, HC, AraC)        | 12, 12, 24 mg             | 5                      |

Abbreviations: AraC, cytarabine; HC, hydrocortisone; IV, intravenously; MTX, methotrexate; TIT, triple intrathecal therapy; TPOG, Taiwan Pediatric Oncology Group.

°TIT is given 24 hours after starting MTX infusion in all course A/B, AA/BB.